Viruses,
Journal Year:
2025,
Volume and Issue:
17(2), P. 207 - 207
Published: Jan. 31, 2025
Understanding
perinatal
health
outcomes
following
SARS-CoV-2
infection
during
pregnancy
necessitates
large-scale
studies
of
mother-infant
dyads.
Hospital-based
pregnant
women
and
their
neonates
provide
valuable
insights
within
the
field
research.
The
aim
this
study
was
to
evaluate
effect
on
maternal
among
hospitalized
in
Rio
de
Janeiro
COVID-19
pandemic.
consisted
a
time-to-event
analysis
hospital-based
cohort
1185
≥
16
years
infants
from
May
2020
March
2022.
Pregnant
were
classified
as
infected
if
they
had
SARS
CoV-2
positive
RT-PCR
or
rapid
antigen
test.
An
exploratory
qualitative
variables
conducted
with
calculation
absolute
relative
frequencies
95%
confidence
intervals.
Survival
functions
estimated
by
Kaplan-Meier
method,
Cox
proportional
hazards
model
employed
interpret
effects
time
adverse
outcomes,
adjusted
for
vaccination,
comorbidity,
gestational
trimester.
A
total
21%
(249/1185)
SARS-CoV-2,
median
age
26
(range:
16-47).
Cesarean
section
deliveries
performed
57%
(135/237)
CoV-2+
participants
vs.
43%
(391/914)
uninfected
participants,
p
<
0.001.
Intensive
care
unit
admission
and/or
death
occurred
68
(5.7%),
44
249
(17.7%)
24
936
(2.5%).
All
21
who
died
unvaccinated
against
COVID-19.
Women
at
greater
risk
(crude
HR:
5.93,
CI:
3.58-9.84;
5.47,
3.16-9.48)
than
women.
vertical
transmission
observed
6
169
(3.6%)
tested
neonates.
Preterm
more
frequently
patients
testing
(30.7%
23.6).
In
survival
analysis,
no
prematurity
(HR:
0.92,
0.68-1.23)
including
fetal
distress
1.29,
0.82-2.05),
stillbirth
1.07,
0.48-2.38),
neonatal
0.96,
0.35-2.67),
even
after
adjusting
trimester,
periods
time.
due
highlights
need
adequate
preventive
measures,
particularly
prenatal
postpartum
periods.
BMJ,
Journal Year:
2022,
Volume and Issue:
unknown, P. e067696 - e067696
Published: March 16, 2022
To
assess
the
rates
of
SARS-CoV-2
positivity
in
babies
born
to
mothers
with
infection,
timing
mother-to-child
transmission
and
perinatal
outcomes,
factors
associated
status
offspring.
Viruses,
Journal Year:
2023,
Volume and Issue:
15(1), P. 175 - 175
Published: Jan. 7, 2023
The
clinical
course
and
outcome
of
COVID-19
are
highly
variable,
ranging
from
asymptomatic
infections
to
severe
disease
death.
Understanding
the
risk
factors
is
relevant
both
in
setting
at
epidemiological
level.
Here,
we
provide
an
overview
host,
viral
environmental
that
have
been
shown
or
(in
some
cases)
hypothesized
be
associated
with
outcomes.
considered
detail
include
age
frailty,
genetic
polymorphisms,
biological
sex
(and
pregnancy),
co-
superinfections,
non-communicable
comorbidities,
immunological
history,
microbiota,
lifestyle
patient;
variation
infecting
dose;
socioeconomic
factors;
air
pollution.
For
each
category,
compile
(sometimes
conflicting)
evidence
for
association
factor
outcomes
(including
strength
effect)
outline
possible
action
mechanisms.
We
also
discuss
complex
interactions
between
various
factors.
Nature Communications,
Journal Year:
2022,
Volume and Issue:
13(1)
Published: July 30, 2022
Studies
are
needed
to
evaluate
the
safety
and
effectiveness
of
mRNA
SARS-CoV-2
vaccination
during
pregnancy,
levels
protection
provided
their
newborns
through
placental
transfer
antibodies.
Here,
we
transplacental
vaccine
products
functional
anti-SARS-CoV-2
antibodies
pregnancy
early
infancy
in
a
cohort
20
individuals
vaccinated
late
pregnancy.
We
find
no
evidence
maternal
blood,
placenta
tissue,
or
cord
blood
at
delivery.
However,
time-dependent
efficient
IgG
neutralizing
neonate
that
persists
infancy.
Additionally,
using
phage
immunoprecipitation
sequencing,
vaccine-specific
signature
Spike
protein
epitope
binding
is
transplacentally
transferred
Timing
critical
ensure
protective
PEDIATRICS,
Journal Year:
2023,
Volume and Issue:
151(5)
Published: April 6, 2023
Long-term
neurodevelopmental
sequelae
are
a
potential
concern
in
neonates
following
utero
exposure
to
severe
acute
respiratory
syndrome
coronavirus
disease
2
(SARS-CoV-2).
We
report
born
SARS-CoV-2
positive
mothers,
who
displayed
early-onset
(day
1)
seizures,
acquired
microcephaly,
and
significant
developmental
delay
over
time.
Sequential
MRI
showed
parenchymal
atrophy
cystic
encephalomalacia.
At
birth,
neither
infant
was
(nasopharyngeal
swab,
reverse
transcription
polymerase
chain
reaction),
but
both
had
detectable
antibodies
increased
blood
inflammatory
markers.
Placentas
from
mothers
SARS-CoV-2-nucleocapsid
protein
spike
glycoprotein
1
the
syncytiotrophoblast,
fetal
vascular
malperfusion,
significantly
oxidative
stress
markers
pyrin
domain
containing
protein,
macrophage
βη,
stromal
cell-derived
factor
1,
interleukin
13,
10,
whereas
human
chorionic
gonadotropin
markedly
decreased.
One
(case
experienced
sudden
unexpected
death
at
13
months
of
age.
The
deceased
infant's
brain
evidence
by
immunofluorescence,
with
colocalization
nucleocapsid
around
nucleus
as
well
within
cytoplasm.
constellation
clinical
findings,
placental
pathology,
immunohistochemical
changes
strongly
suggests
that
second-trimester
maternal
infection
placentitis
triggered
an
response
injury
fetoplacental
unit
affected
brain.
demonstration
also
raises
possibility
directly
contributed
ongoing
injury.
In
infants,
neurologic
findings
birth
mimicked
presentation
hypoxic-ischemic
encephalopathy
newborn
progressed
beyond
neonatal
period.
Nature Communications,
Journal Year:
2023,
Volume and Issue:
14(1)
Published: Jan. 6, 2023
Abstract
Evidence
on
associations
between
COVID-19
vaccination
or
SARS-CoV-2
infection
and
the
risk
of
congenital
anomalies
is
limited.
Here
we
report
a
national,
population-based,
matched
cohort
study
using
linked
electronic
health
records
from
Scotland
(May
2020-April
2022)
to
estimate
association
and,
separately,
six
weeks
pre-conception
19
days
gestation
[1]
any
major
anomaly
[2]
non-genetic
anomaly.
Mothers
vaccinated
in
this
pregnancy
exposure
period
mostly
received
an
mRNA
vaccine
(73.7%
Pfizer-BioNTech
BNT162b2
7.9%
Moderna
mRNA-1273).
Of
6731
babies
whose
mothers
were
period,
153
had
120
Primary
analyses
find
no
(adjusted
Odds
Ratio
[aOR]
=
1.01,
95%
Confidence
Interval
[CI]
0.83-1.24)
(aOR
1.00,
CI
0.81-1.22).
also
1.02,
0.66-1.60)
0.94,
0.57-1.54).
Findings
are
robust
sensitivity
analyses.
These
data
provide
reassurance
safety
vaccination,
particular
vaccines,
just
before
early
pregnancy.
Biology of Reproduction,
Journal Year:
2022,
Volume and Issue:
108(2), P. 172 - 182
Published: Sept. 29, 2022
Abstract
Coronavirus
disease
2019
(COVID-19)
is
a
multi-system
that
has
led
to
pandemic
with
unprecedented
ramifications.
The
challenged
scientists
for
the
past
2
years
and
brought
back
previously
abandoned
research
topics.
COVID-19
infection
causes
myriad
of
symptoms
ranging
from
mild
flu-like
severe
illness
requiring
hospitalization.
Case
reports
showed
multiple
systemic
effects
infection,
including
acute
respiratory
distress
syndrome,
fibrosis,
colitis,
thyroiditis,
demyelinating
syndromes,
mania,
indicating
can
affect
most
human
body
systems.
Unsurprisingly,
major
concern
women
all
over
globe
whether
any
long-term
on
their
menstrual
cycle,
fertility,
or
pregnancy.
Published
data
have
suggested
an
effect
reproductive
health,
we
hypothesize
reported
adverse
are
due
robust
immune
reaction
against
associated
cytokine
storm.
While
receptor
(angiotensin
converting
enzyme,
ACE2)
expressed
in
ovaries,
uterus,
vagina,
placenta,
it
plays
less
important
role
system.
Cytokines
glucocorticoids
act
hypothalamo–pituitary
gonadal
axis,
arachidonic
acid
pathways,
which
leads
disturbances
pregnancy-related
events
such
as
preterm
labor
miscarriages.
This
hypothesis
further
supported
by
apparent
lack
health
females,
when
storm
its
dampened,
no
longer
affected.